Hookipa Pharma (HOOK) Receives New Coverage from Analysts at Leerink Swann

Leerink Swann started coverage on shares of Hookipa Pharma (NASDAQ:HOOK) in a report published on Monday morning, Benzinga’s Daily Ratings Newsletter reports. The firm issued an outperform rating and a $20.00 price target on the stock.

Several other research firms have also recently weighed in on HOOK. Bank of America initiated coverage on shares of Hookipa Pharma in a report on Monday. They issued a buy rating and a $17.00 price target for the company. Svb Leerink initiated coverage on shares of Hookipa Pharma in a report on Monday. They issued an outperform rating and a $20.00 price target for the company. Finally, Royal Bank of Canada initiated coverage on shares of Hookipa Pharma in a report on Monday. They issued an outperform rating and a $23.00 price target for the company.

Hookipa Pharma stock opened at $13.25 on Monday. Hookipa Pharma has a twelve month low of $12.62 and a twelve month high of $14.76.

In other Hookipa Pharma news, insider Bros. Advisors Lp Baker acquired 892,857 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The shares were acquired at an average price of $14.00 per share, with a total value of $12,499,998.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Sofinnova Capital Vi Fcpr acquired 357,142 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $4,999,988.00. The disclosure for this purchase can be found here.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Featured Article: What is a Call Option?

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.